Monthly Archives: May 2011

The Most Influential Pharma Leader Or Institution?

By Julian Upton | Published: May 25, 2011
Ahead of Pharm Exec’s 30th Anniversary Issue later this year, we are assembling a list of pharma leaders who have made the most impact on the industry. Which individual(s) or institution(s) do you think has had the most influence of the industry in the last 10–30 years? Please leave a comment in the box below or drop [...]
Posted in People, leadership | Tagged , , , , | 10 Comments

CBI Conference Highlights Innovative Programs on Patient Compliance

By Jennifer Ringler | Published: May 25, 2011
With compliance rates flagging, companies have to work harder than ever to demonstrate these programs have value and represent a good ROI Pharm Exec’s sister conference organization, CBI, sponsored its 10th annual Patient Adherence Forum in April to highlight current trends in industry compliance and adherence programs — where companies reach out to help an increasingly skittish [...]
Posted in Events, patient compliance | Tagged , , | Leave a comment

Florida Builds on Biotech Industry

By Jennifer Ringler | Published: May 23, 2011
While the biotechnology industry has weakened across the U.S., Florida has seen a 21 percent jump in the number of biotech companies since 2008 and a surge in investment, according to the University of Florida. Updated numbers from the Florida BioDatabase, maintained by the University of Florida’s Sid Martin Biotechnology Incubator. in Alachua, show 29 new [...]
Posted in Biotech | Tagged , , | Leave a comment

With Botanicals, No Patent, No Expiry, says Sanofi Exec

By Ben Comer | Published: May 20, 2011
What if a new drug could be trademarked instead of patented, keeping generics companies at bay for the life of the trademark, i.e., forever? That was one of the ideas floated to reporters yesterday by Sanofi-Aventis’ Ray Jupp, VP of the fibrosis and wound repair therapeutic strategic unit, an early-stage research division created as part of [...]
Posted in R&D, Strategy | Tagged , , , , , | 3 Comments

Whither the Market Research Function?

By William Looney | Published: May 20, 2011
PBIRG’s 50th anniversary meeting strikes a note for change—because the alternative is a drift toward organizational irrelevance It’s easy to be complacent about the harsh competitive challenges facing Big Pharma today. We all know what these challenges are, and the temptation is to address them in the abstract. As if all this complexity can be [...]
Posted in Strategy | 1 Comment